Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Oxagen announces completion of recruitment in Phase IIb dose range-finding clinical trial ...

Oxagen announces completion of recruitment in Phase IIb dose range-finding clinical trial in new oral treatment for asthma

Abingdon, Oxford, UK, 9th December 2009 – Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.

The study, which was initiated in mid May 2009, is expected to complete by the end of Q2 2010. It involves 440 asthmatic patients with moderate persistent asthma who will be randomised to one of three possible dose levels of OC000459 or placebo by oral tablet for a 12 week dosing period, with lung function (improvement in clinic FEV1) being the primary end point.

The purpose of the study is to determine the magnitude of further improvement in lung function and asthma symptoms on longer term therapy and to define the optimal once daily oral dose of OC000459.

Mark Payton PhD, Oxagen’s Chief Executive Officer said ”This represents an exciting time for Oxagen and a key phase in the clinical development of this compound following our recent successful proof-of–concept studies in both asthma and allergic rhinitis. We believe oral CRTH2 antagonists offer a valuable contribution to respiratory medicine and this study maintains Oxagen’s position as one of the leading players in this field.”

The Phase IIb trial follows the successful completion of a Phase IIa programme in which four Phase IIa trials were completed with efficacy demonstrated in asthma and allergic rhinoconjunctivitis. Over 600 subjects have been treated with OC000459 to date and results so far indicate the drug to be well tolerated.

Oxagen recently completed a £16 Million ($26.7 Million) Series C financing led by Novartis Venture Funds. The proceeds of the funding are being used primarily to advance the Company’s CRTH2 antagonist programme in inflammatory and respiratory diseases, including the completion of this Phase IIb clinical study of OC000459 in moderate persistent asthma.


Notes for Editors:

About Oxagen

Oxagen is a biopharmaceutical company building a novel drug pipeline with a focus on inflammatory and respiratory diseases. Oxagen’s pipeline of novel small molecule drugs is based on targets validated in man.

Oxagen was established in April 1997. The Company is based in Milton Park, south of Oxford. For more information on Oxagen, please visit

About CRTH2 and OC000459

The G-protein coupled receptor, CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells also known as DP2) mediates allergic responses by interaction with the mast cell product prostaglandin D2. There is now overwhelming evidence that CRTH2 plays a central role in the recruitment of leukocytes and their activation to elaborate Th2 cytokines in allergic disease, findings which highlight the potential therapeutic utility of CRTH2 antagonists.

OC000459 is a potent, selective and orally active CRTH2 antagonist, effective in reducing the recruitment and activation of Th2 lymphocytes, eosinophils and other cell types to sites of allergic inflammation.

Media enquiries to

College Hill - Sue Charles, Cosima Toepfer


T: +44 (0)20 7866 7861

At Oxagen

Dr Mark Payton, CEO


T: +44 (0)1235 443311

Publisher Contact Information:

Oxagen Limited
+44 (0)1235 443311

Company profile of Oxagen Limited
Past press releases of Oxagen Limited.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.